Oragenics, Inc. Announces Closing of Public Offering
SARASOTA, Fla., June 26, 2024 (GLOBE NEWSWIRE) — Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal…
Pharmaceuticals, Biotechnology and Life Sciences
SARASOTA, Fla., June 26, 2024 (GLOBE NEWSWIRE) — Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal…
Company announcement – No. 35 / 2024 Zealand Pharma announces completion of an upsized equity offering of 8.35 million new…
DALLAS, June 25, 2024 (GLOBE NEWSWIRE) — Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing…
ANX005-Treated Patients Demonstrated Faster and More Complete Recovery from Week 1 through Week 26 on Primary and Multiple Pre-Specified Endpoints…
SARASOTA, Fla., June 24, 2024 (GLOBE NEWSWIRE) — Oragenics, Inc. (NYSE: OGEN) (“Oragenics” or the “Company”), a company focused on…
– Corporate culture remains a strength as the company experienced dynamic growth -CLEVELAND, June 23, 2024 (GLOBE NEWSWIRE) — SPR…
Novo Nordisk announced results from the phase 3 FRONTIER2 trial of 254 adults and adolescents aged 12 years and over…
Pemvidutide elicited significant weight loss and decreases in pro-inflammatory serum lipids associated with atherogenesis and cardiovascular disease riskGAITHERSBURG, Md., June…
TERN-501 significantly improved the efficacy of a GLP-1 receptor agonist by normalizing energy expenditure, resulting in greater weight loss, increased…
Lantheus has agreed to make an initial strategic equity investment of A$7.5 million in RadiopharmOffer price for the shares of…